Lumida
/CI
⌘K
Cigna Group

Cigna Group

CI
$289.57USD↑+1.15%+3.28 today

MARKET CAP

76.6B

P/E (TTM)

9.4x

FWD P/E

8.9x

DAY RANGE

$286 – $291

52W RANGE

$240
$315

AI Summary

Stalk
Sell NowMedium

CI remains in a Stage 3 distribution regime with key EMAs and the 50 DMA acting as resistance, reinforcing a medium-term bearish bias. Price repeatedly fails to sustain above the 9/21 EMAs and 50 DMA, and short-term momentum is negative as RSI sits below midline and price rejects at dynamic resistances. The Bullish Pivot Point did not lead to lasting upside, signaling continued supply dominance. Execution should be active on rallies into the EMAs or near the 50 DMA, selling now into these resistance zones.

  • ↑Q1 net revenue $68.5B (+9% YoY) with adjusted EPS $7.79 (+16%).
  • ↑Raised 2026 adjusted EPS guidance to ≥$30.35, reflecting strong execution.
  • ↓Negative profitability factors suggest near-term margin compression.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Cigna Group (NYSE: CI) is a leading global health services organization that offers a wide range of integrated healthcare solutions, including health insurance, pharmacy benefit management, and specialty care services. As a prominent player in the managed care sector, Cigna is well-positioned to tackle the increasing demands for healthcare affordability and personalized services, especially in the context of rising costs in the healthcare system. Their Evernorth division, focused on health services, plays a significant role in driving innovation and growth, particularly within specialty pharmacy.

Bull says

  • ↑Q1 net revenue $68.5B (+9% YoY) with adjusted EPS $7.79 (+16%).
  • ↑Raised 2026 adjusted EPS guidance to ≥$30.35, reflecting strong execution.
  • ↑Evernorth specialty pharmacy segment earnings grew 20% in Q1.
  • ↑Declared $1.56/share dividend (1.05% yield) and $2.6B share buybacks.
  • ↑Transition to rebate-free pharmacy model aims at lower out-of-pocket costs.
  • ↑Bernstein maintains Outperform rating; $381 price target implies upside.

Bear says

  • ↓Negative profitability factors suggest near-term margin compression.
  • ↓Individual exchange members to decline, dampening revenue growth.
  • ↓~$1.3B capex for benefit model transition may strain cash flow.
  • ↓Heightened regulatory scrutiny on drug pricing could squeeze margins.
  • ↓Short-term cost headwinds expected to lower contributions to cash flow.
  • ↓Weak institutional interest amid low 13F ownership raises concern.

Investment themes with CI

High Dividend Yield↑ +0.32%

Companies paying above-average dividends

AVGO · JPM · XOM
Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-30-2026neutral

Transcript signals

Bull points

  • We're really pleased with the performance of the overall Cigna Healthcare business and also excited to be able to raise the guide for the year based on what we're seeing so far, which includes an appropriate degree of prudence for the balance of the year.
  • we started the year with strong results across both Evernote Health Services and Cigna Healthcare. Overall, Evernote earnings were slightly ahead of expectations. This was driven by the strength of our specialty and care services businesses, which delivered adjusted earnings growth of 20% in the quarter, reflecting continued attractive volume growth.
  • As a result of this combined strength, we are pleased to increase our earnings guidance for the year to at least $30.35 per share.

Bear points

  • the ongoing tension here is affordability versus employee and family member satisfaction. So employers know this is a very popular benefit. They also know that it's a net cost right now to their overall health care programs.
  • we are planning to exit our individual exchange business at the end of this year. We did not make this decision lightly and appreciate the importance of ensuring patients have continuity through the transition.
  • Our first quarter results reflect previously discussed impacts of large client renewals and investments as we progress toward our transformative new rebate-free model, aptly named Signature.
Read full transcript analysis ›